Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin®)

被引：0
作者：
C. Chiesa
F. Botta
A. Coliva
M. Maccauro
L. Devizzi
A. Guidetti
C. Carlo-Stella
E. Seregni
M. A. Gianni
E. Bombardieri
机构：
[1] Foundation IRCCS Istituto Nazionale Tumori,Nuclear Medicine Division
[2] University of Milan,Health Physics Postgraduate School
[3] Foundation IRCCS Istituto Nazionale Tumori,“Cristina Gandini” Medical Oncology
[4] University of Milan,Medical Oncology
来源：
European Journal of Nuclear Medicine and Molecular Imaging | 2009年 / 36卷
关键词：
Lymphoma; Therapy; RIT dosimetry;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1745 / 1757
页数：12
相关论文
共 184 条
  • [91] Chauvin F(undefined)undefined undefined undefined undefined-undefined
  • [92] Gogou L(undefined)undefined undefined undefined undefined-undefined
  • [93] Emami B(undefined)undefined undefined undefined undefined-undefined
  • [94] Lyman J(undefined)undefined undefined undefined undefined-undefined
  • [95] Brown A(undefined)undefined undefined undefined undefined-undefined
  • [96] Coia L(undefined)undefined undefined undefined undefined-undefined
  • [97] Goitein M(undefined)undefined undefined undefined undefined-undefined
  • [98] Munzenrider JE(undefined)undefined undefined undefined undefined-undefined
  • [99] Chiesa C(undefined)undefined undefined undefined undefined-undefined
  • [100] Botta F(undefined)undefined undefined undefined undefined-undefined
567891011121314